StockData
Pfizer Inc logo

Pfizer Inc

PFENYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 28, 2026Last filing: 10-Q on Nov 3, 2026Score 11/3056% above fair value
$30.52+0.57 (+1.90%)

Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%

Pfizer Sulperazon (cefoperazone/sulbactam by Year

Sulperazon (cefoperazone/sulbactam — hospital anti-infective) — International reported YoY (%) (%)

Pfizer Sulperazon (cefoperazone/sulbactam: 2.0% in FY2025, up 18.0 pts from a year earlier.

Latest, FY2025
2.0%
Period ended Dec 31, 2025
Change on a year earlier
+18.0 pts
-16.0% in FY2024
History
9 years
Since FY2017
Sources
9
Documents cited below

Where the FY2025 figure comes from

“|| Sulperazon (Outside the U.S. and Canada) | 653 | 637 | 2% | 3% | — | — | — | 653 | 637 | 2% | 3%”

Source: Form 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗

Reported in Form 8-K Revenue Tables.

Annual history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedSulperazon (cefoperazone/sulbactam — hospital anti-infective) — International reported YoY (%) (%)Year on yearSource
FY2025Dec 31, 20252.0%+18.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312025xex99.htm, filed 2026-02-03) ↗
FY2024Dec 31, 2024-16.0%-12.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312024xex99.htm, filed 2025-02-04) ↗
FY2023Dec 31, 2023-4.0%-19.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
FY2022Dec 31, 202215.0%+4.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗
FY2021Dec 31, 202111.0%+21.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312021xex99.htm, filed 2022-02-08) ↗
FY2020Dec 31, 2020-10.0%-22.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312020xex99.htm, filed 2021-02-02) ↗
FY2019Dec 31, 201912.0%-18.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312019xex99.htm, filed 2020-01-28) ↗
FY2018Dec 31, 201830.0%+11.0 ptsForm 8-K (Earnings / Guidance Release) (pfe-12312018xex99.htm, filed 2019-01-29) ↗
FY2017Dec 31, 201719.0%–Form 8-K (Earnings / Guidance Release) (pfe-12312017xex99.htm, filed 2018-01-30) ↗

Cite this data

StockData. (2026). Pfizer Sulperazon (cefoperazone/sulbactam (%), annual FY2017–FY2025 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/sulperazon-yoy-intl

See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.